Janney Montgomery Scott LLC Has $141.09 Million Holdings in Amgen Inc. $AMGN

Janney Montgomery Scott LLC increased its holdings in Amgen Inc. (NASDAQ:AMGN) by 10.4% during the fourth quarter, HoldingsChannel reports. The fund owned 431,053 shares of the medical research company’s stock after acquiring an additional 40,622 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Amgen were worth $141,088,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in AMGN. Brighton Jones LLC raised its holdings in shares of Amgen by 23.5% in the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after acquiring an additional 5,226 shares during the last quarter. Sivia Capital Partners LLC raised its holdings in shares of Amgen by 10.6% in the 2nd quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock worth $331,000 after acquiring an additional 114 shares during the last quarter. Schnieders Capital Management LLC. raised its holdings in shares of Amgen by 29.3% in the 2nd quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock worth $7,220,000 after acquiring an additional 5,853 shares during the last quarter. Main Street Financial Solutions LLC raised its holdings in shares of Amgen by 11.3% in the 2nd quarter. Main Street Financial Solutions LLC now owns 4,086 shares of the medical research company’s stock worth $1,141,000 after acquiring an additional 416 shares during the last quarter. Finally, Ieq Capital LLC raised its holdings in shares of Amgen by 5.1% in the 2nd quarter. Ieq Capital LLC now owns 54,152 shares of the medical research company’s stock worth $15,120,000 after acquiring an additional 2,611 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen’s obesity drug MariTide is drawing attention as a potential growth driver, with analysts noting that its less frequent dosing could help the company compete in the fast-growing GLP-1/obesity market. Article Title
• Positive Sentiment: Amgen’s broader growth pipeline is being viewed as a potential offset to patent-related pressure, with some commentary suggesting 2026 could be a “springboard” year if newer drugs gain traction. Article Title
• Neutral Sentiment: Goldman Sachs trimmed its price target on Amgen but kept a Buy rating, signaling some caution on valuation while still seeing upside potential. Article Title
• Neutral Sentiment: Recent market commentary noted that Amgen has underperformed some peers and posted a bigger drop than the broader market, reflecting short-term profit-taking and weaker relative momentum. Article Title
• Negative Sentiment: Market coverage also flagged that Amgen fell more than the market in the latest session, reinforcing concern that investors may be locking in gains after the stock’s strong multi-year run. Article Title

Amgen Trading Down 2.0%

NASDAQ:AMGN opened at $337.73 on Thursday. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. The firm has a market cap of $182.28 billion, a price-to-earnings ratio of 23.50, a price-to-earnings-growth ratio of 3.46 and a beta of 0.42. Amgen Inc. has a 52 week low of $267.83 and a 52 week high of $391.29. The firm has a 50-day moving average price of $340.89 and a two-hundred day moving average price of $345.53.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. During the same quarter last year, the business posted $4.90 EPS. The company’s revenue for the quarter was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, equities analysts expect that Amgen Inc. will post 22.38 earnings per share for the current fiscal year.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares in the company, valued at $2,269,023.57. This trade represents a 15.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.85% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research firms recently weighed in on AMGN. Daiwa Securities Group lowered their target price on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating on the stock in a report on Wednesday, May 13th. Canaccord Genuity Group initiated coverage on shares of Amgen in a research note on Monday, April 20th. They issued a “hold” rating and a $366.00 price objective for the company. Barclays initiated coverage on shares of Amgen in a research note on Friday, February 20th. They issued an “equal weight” rating and a $350.00 price objective for the company. Wall Street Zen lowered shares of Amgen from a “buy” rating to a “hold” rating in a research note on Saturday, June 6th. Finally, The Goldman Sachs Group set a $389.00 price objective on shares of Amgen in a research note on Friday, June 5th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $354.12.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.